Galeanu Mihai/iStock via Getty Images Investment Outlook Freshworks Inc. ( FRSH ) reported its Q4 2025 and full-year financial results , beating revenue and earnings estimates for the final quarter of 2025, with earnings growth due to one-time factors. I previously analyzed FRSH in April 2025 with a neutral Hold outlook due to international revenue uncertainties. The company is producing mid-teens revenue growth while integrating GenAI capabilities in its EX system and generating AI revenue, though still a small percentage. With ample resources to continue upgrading its systems and buying back stock, the firm appears increasingly well-positioned to fend off disruption in the middle market and larger enterprise space, but the low end of its market may be a source of greater churn, so I remain a neutral Hold for the time being. Freshworks’ Market and Approach Freshworks provides employee and customer experience software delivered via the cloud, primarily generating revenue on a per-seat basis as a SaaS company, and markets its software worldwide. The global market for customer service and related software was an estimated $14.9 billion in 2024 and was projected to exceed $68 billion by 2032, according to a Verified Market Research report . If achieved, this growth rate would equal a CAGR of nearly 21% from 2025 to 2032, a very high rate of growth. Customer demand has evolved from simple ticketing systems to far more sophisticated AI-driven platforms that triage and manage post-purchase customer interactions as well as internal employee journeys. More recently, vendors have been adding GenAI capabilities as immediate response systems for less complex workloads, escalating more complicated actions for human intervention. The chart below shows the expected growth path of the customer service market through 2032: Verified Market Research FRSH also provides employee engagement software solutions. That market was an estimated $928 million in 2023 and was forecasted to excee...

Context Therapeutics press release ( CNTX ): FY GAAP EPS of -$0.38. Cash and cash equivalents were $66.0 million at December 31, 2025, compared to $94.4 million at December 31, 2024. More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics

3月24日热门中概股多数上涨， 纳斯达克 中国金龙指数（HXC）收高0.86%。 上涨股当中（按市值从高到低）， 台积电 涨2.78%、 阿里 巴巴 涨2.99%、 拼多多 涨0.06%、 日月光半导体 涨1.74%、 百度 涨0.24%、 京东 涨0.99%、携程涨0.51%、 中华电信 涨1.03%、 中通 涨1.92%、 富途 控股涨3.72%、 理想 汽车涨2.57%、小鹏汽车涨7.52%、 蔚来 涨7.00%、 哔哩哔哩 涨0.75%、 新东方 涨0.13%、满帮涨0.24%、万国数据涨2.22%、 唯品会 涨1.36%、WSP控股涨1.27%、拓臻生物涨2.42%、名创优品涨0.74%、小马智行涨4.84%、 金山云 涨3.24%、禾赛科技涨3.19%、微牛涨3.51%。 下跌股当中（按市值从高到低）， 网易 跌0.35%、 联电 跌0.49%、 贝壳 跌2.93%、 腾讯音乐 跌1.29%、 华住酒店集团 跌0.76%、中国新城农村跌3.77%、BOSS直聘跌2.05%、亚朵集团跌2.55%、 慧荣科技 跌0.02%、欢聚跌1.12%、 雾芯 科技跌2.75%。 美股周一收高，但三大指数均已从盘中最高点大幅回落。美国总统特朗普表示美伊双方已举行会谈，且他已叫停对伊朗发电厂及能源基础设施的打击行动，为投资者带来希望——此前推高油价并引发全球衰退担忧的中东冲突或正接近尾声。 道指涨631.00点，涨幅为1.38%，报46208.47点；纳指涨299.15点，涨幅为1.38%，报21946.76点；标普500指数涨74.52点，涨幅为1.15%，报6581.00点。 三大美国股指盘中高点涨幅均超2%。道指最高上涨逾1100点，涨幅达2.5%；纳斯达克指数最高上涨2.5%；标普500指数最高上涨2.2%。 领涨中概股列表： 领跌中概股列表： （截图来自新浪财经APP 行情-美股-中概股热门板块）下载新浪财经APP 责任编辑：张俊 SF065

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Micron Technology. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends C3.ai. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

A California jury found Bill Cosby guilty of sexual assault in a civil trial on Monday, awarding Donna Motsinger $19.25m in damages. Motsinger alleged in the case that while working as a restaurant server in 1972, she was drugged and raped by Cosby after he gave her a glass of wine in his limousine. Motsinger sued Cosby after California amended its laws to change the statutes of limitations on when accusers can file sexual assault cases. In remarks after the jury’s verdict, she described the trial as a five-decade-long effort to get justice. Cosby, once one of the most successful men in comedy and an entertainment icon, has largely disappeared from public view in the past decade amid widespread allegations of sexual misconduct. In addition to the dozens of women who have accused Cosby of drugging and sexual assault, he has faced a series of civil trials – including Los Angeles county jurors in 2022 finding that he sexually assaulted a 16-year-old girl at the Playboy mansion in 1975. Cosby spent three years in prison after being convicted of sexual assault in 2018, but was released in 2021 after a higher court reversed the decision. The higher court found that prosecutors had violated Cosby’s rights by promising not to charge him and then later pursuing a case against him. A lawyer for Cosby stated that he plans to appeal Monday’s verdict.

Public Policy Holding Company, Inc. press release ( PPHC ): Q4 Non-GAAP EPS of $0.42 misses by $0.01 . Revenue of $49.9M (+27.9% Y/Y) in-line. More on Public Policy Holding Company, Inc. PPHC announces acquisition of WPI Strategy Historical earnings data for Public Policy Holding Company, Inc. Financial information for Public Policy Holding Company, Inc.

Tesla and SpaceX will jointly run an advanced chip manufacturing facility in Austin, Texas, according to Elon Musk, the CEO of both companies. Bloomberg's Loren Grush joins Caroline Hyde and Ed Ludlow to discuss Musk’s Terafab project on “Bloomberg Tech.” (Source: Bloomberg)

Key Points Pfizer has underperformed the market in each of the past three years. The stock is doing well of late as investors have been turning to safer investments amid uncertainty. Pfizer has been struggling to grow in recent years, and it faces plenty of uncertainty ahead. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost confidence in the company's ability to grow, as it loses patent protection on key drugs and faces an uncertain future. Besides a dividend, there hasn't been a compelling reason for investors to buy shares of Pfizer. But this year, with there being more concern in the markets and investors piling into dividend stocks, Pfizer has suddenly become a more enticing option. As a result, the stock is doing something it hasn't done in multiple years -- it's outperforming the S&P 500. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The last time Pfizer's stock outperformed the S&P 500 was in 2022 As growth stocks have been in high demand over the past couple of years, investors have largely looked past Pfizer due to the question marks surrounding the company's future. In 2025, shares of the healthcare giant fell by 6%. The year before that, they were down by 8%, after crashing 44% in 2023. Even in 2022, the stock declined by 13%, but that was a year when the S&P 500 fell by 19% as high inflation weighed on the markets as a whole. And that was the last time that Pfizer proved to be a market-beating stock. This year is playing out the same way, and for comparable reasons. Investors are worried about the state of the economy, commodity prices are rising, and there are multiple wars taking place. There are an a...

Key Points Joby Aviation's business model differs significantly from that of its peers. There's reason to believe its vertically integrated strategy will win out. The upside potential is significant; provided the certification process goes smoothly, Joby has a big future. 10 stocks we like better than Joby Aviation › The electric vertical take-off and landing (eVTOL) market is crowded, but that doesn't mean it's a winner-takes-all scenario. Different companies have different business models with varying risks and rewards, and Joby Aviation (NYSE: JOBY) is arguably the one with the most reward and also one that's reducing its risk the most in 2025. Is it enough to make it a stock that could set investors up for life? Here's the lowdown. What makes Joby Aviation different It's always interesting to compare competitors across a growth industry, and doing so with Joby's peer Archer Aviation (NYSE: ACHR) makes for a fascinating comparison. The first conclusion is that they have significantly different models. The second is that the nature of their models allows for more than enough room for both in the market, and the third is that Joby Aviation is making real progress in de-risking the elements of its business that are subject to greater market uncertainty. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » In a nutshell, you can think of Joby Aviation as a "go it alone" player in the industry, backed by a heavyweight manufacturing partner in Toyota, as well as other investors such as Uber and Delta Air Lines. Its business model is different from Archer's and the rest of the industry in two key ways: Joby Aviation doesn't plan to sell its aircraft and prefers to develop much of its technology in-house, having its own powertrain and electronics manufacturing facility in California. As quoted from its Securities and Exchange Commission (SEC) filings, Joby plans to "own and operate our ai...

watch now VIDEO 9:30 09:30 Watch CNBC's full interview with U.S. Interior Secretary Doug Burgum Power Lunch HOUSTON — Asian countries want to buy more U.S. energy to reduce their dependence on oil and gas exports from the Middle East, Interior Secretary Doug Burgum told CNBC on Monday. Japan, South Korea and Taiwan rely heavily on exports through the Strait of Hormuz. Oil tanker traffic through the strait has plunged as Iran attacks commercial ships in the Persian Gulf. "They want to buy more energy from the U.S.," Burgum told CNBC's Brian Sullivan in an interview. President Donald Trump's energy dominance agenda is designed to provide U.S. allies with a stable, alternative supply of energy, the Interior secretary said. The U.S. is the largest oil and gas producer in the world. "Our allies and our friends can buy from us as opposed to having to buy from countries that either wage war or fund terrorism," said Burgum, who travelled to Japan earlier this month. The U.S. and Israeli attack on Iran has triggered the largest oil supply disruption in history. Tokyo relies on the strait for 90% of its oil imports, said Takehiko Matsuo, a vice minister at Japan's Ministry of Economy, Trade and Industry. "The impact is significant," Matsuo said at S&P Global's CERAWeek conference in Houston, Texas. Japan has placed a high priority on finding alternative supplies, he said. "I must say it's not easy," the vice minister said. "The United States is one of the most anticipated alternative energy source for Asian countries." Asian economies are also heavily dependent on liquefied natural gas (LNG) exports through the strait. Iranian attacks on Qatar's energy infrastructure has shut down about 20% of the world's LNG supplies. Alaska will play a major role in providing Asia with secure energy, Burgum said. The Interior Department recently held an oil and gas lease sale for the National Petroleum Reserve in Alaska. The Trump administration has also made an massive LNG project in Alask...

fokkebok/iStock via Getty Images Canadian renewable energy firm Boralex ( BRLXF ) is weighing its options, including a potential deal to go private , and is working with Canadian banks to handle proposals, Bloomberg reported Monday. Boralex's ( BRLXF ) stock price is trading at a little more than half of its 2021 peak as the company copes with industry-wide headwinds, including political opposition by the Trump administration to wind power in the U.S. A year ago, Caisse de Depot et Placement du Quebec agreed to take private Boralex's ( BRLXF ) biggest local rival, Innergex Renewable Energy, in a deal worth ~C$10B (US$7.3B) including debt; La Caisse also is Boralex's largest shareholder, with a 15% stake, according to data compiled by Bloomberg. The Boralex ( BRLXF ) board's deliberations are early, and the company could still decide to remain public, according to the report. More on Boralex Boralex Q4 2025 Earnings Call Presentation Boralex Q4 2025 Earnings Call Transcript Boralex: Underfollowed Renewable Energy Company Trading At A Discount

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Figma. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec. (Source: Bloomberg)

Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy Reuters

US equity indexes closed higher on Monday as crude oil prices tumbled after President Donald Trump d Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles.

JERSEY CITY, NJ / ACCESS Newswire / March 23, 2026 / Amdocs (NASDAQ:DOX) ("Amdocs" or the "Company"), a leading provider of software and services to communications and media companies, today announced that, in connection with his retirement from Amdocs' management team, Shuky Sheffer has also retired from Amdocs' Board of Directors (the "Board") and the Board has appointed Shimie Hortig as a new member of the Board, effective concurrently with Mr. Hortig's replacement of Mr. Sheffer as President and Chief Executive Officer of Amdocs Management Limited. Supporting Resources Keep up with Amdocs news by visiting the company's website Follow us on X, Facebook, LinkedIn and YouTube About Amdocs Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com . Amdocs' Forward-Looking Statement This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking ...

The management team at this company has done an excellent job of adapting to unprecedented circumstances over the past six years. *Stock prices used were the afternoon prices of March 20, 2026. The video was published on March 22, 2026. Continue reading

Abivax press release ( ABVX ): FY The Company had cash, cash equivalents, and short-term investments of €530.4 million as of December 31, 2025, providing a projected cash runway into Q4 2027 based on current operating assumptions. Research and development (“R&D”) expenses increased by €31.2 million to €177.8 million (70.9% of operating expenses) in 2025 compared to €146.5 million (79.0% of operating expenses) in 2024. More on Abivax Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement Abivax: Don't Just Buy The Rumor, Buy The Fundamentals Abivax pares gain after denying AstraZeneca speculation Abivax CEO responds to Lilly acquisition rumors Seeking Alpha’s Quant Rating on Abivax

IBM (NYSE: IBM) stock is yet another business impacted by the rising effectiveness of AI. *Stock prices used were the afternoon prices of March 20, 2026. The video was published on March 22, 2026. Continue reading